ACTX
ADVANCED CONTAINER
stock OTC

Biotech has been shaky in 2025, but if there’s one thing that can move the needle, it’s new biomarker data, and that’s exactly what Actuate Therapeutics ($ACTX) just delivered.
**The Update**
Actuate reported positive biomarker data from its ongoing Phase 2 trial of *elraglusib* in glioblastoma (GBM) patients, one of the most aggressive and difficult-to-treat cancers.
**Why It Matters**
The study showed a correlation between patient outcomes and immune-related gene expression, particularly PD-L1 and TIM-3.
Patients with higher levels of these markers showed better progression-free survival.
This could help identify which patients respond early, improving trial design or attracting partnership opportunities.
Volume has remained low, and it’s not the kind of headline that will immediately send a stock flying, but for those doing deeper research, this is the kind of update that builds long-term value. Also Looking at the chart below is has been getting hounded the past few weeks.
Not flashy, but one of those "save this for later" type of moments.
https://preview.redd.it/q4rnrge1ap8f1.png?width=2266&format=png&auto=webp&s=ae7388b8909ec3ad7939f5a3b4dac4c39384a0d2
Communicated Disclaimer: This is not financial advice. please continue your DD and learn more about this company! - Sources - [1](http://actuatetherapeutics.com/), [2](https://finance.yahoo.com/news/actuate-therapeutics-presents-topline-elraglusib-203000713.html), [3](https://chartingdaily.com/Actu)

Biotech has been shaky in 2025, but if there’s one thing that can move the needle, it’s new biomarker data, and that’s exactly what Actuate Therapeutics ($ACTX) just delivered.
**The Update**
Actuate reported positive biomarker data from its ongoing Phase 2 trial of *elraglusib* in glioblastoma (GBM) patients, one of the most aggressive and difficult-to-treat cancers.
**Why It Matters**
The study showed a correlation between patient outcomes and immune-related gene expression, particularly PD-L1 and TIM-3.
Patients with higher levels of these markers showed better progression-free survival.
This could help identify which patients respond early, improving trial design or attracting partnership opportunities.
Volume has remained low, and it’s not the kind of headline that will immediately send a stock flying, but for those doing deeper research, this is the kind of update that builds long-term value. Also Looking at the chart below is has been getting hounded the past few weeks.
Not flashy, but one of those "save this for later" type of moments.
https://preview.redd.it/q4rnrge1ap8f1.png?width=2266&format=png&auto=webp&s=ae7388b8909ec3ad7939f5a3b4dac4c39384a0d2
Communicated Disclaimer: This is not financial advice. please continue your DD and learn more about this company! - Sources - [1](http://actuatetherapeutics.com/), [2](https://finance.yahoo.com/news/actuate-therapeutics-presents-topline-elraglusib-203000713.html), [3](https://chartingdaily.com/Actu)